What is the purpose of this trial?
The available data indicate that Ceritinib has substantial anti-tumor activity in patients with anaplastic lymphoma kinase (ALK) and ROS1 rearranged non-small cell lung cancer (NSCLC). This trial will investigate the potential of Ceritinib in patients with advanced gastrointestinal malignancies with ALK and ROA1 rearrangement, and for whom there is no available therapeutic option.
Ages: 18 years and older
Academic GI Cancer Consortium (AGICC)
Dates: 11/30/2016 - 08/31/2017
Last Updated: 12/20/2017
Study HIC#: 1606018017